Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
- Bill Number
- H.R. 1796
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-03: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-02-05T17:34:04Z
AI-Generated Summary
Purpose
This legislation aims to reauthorize and expand a federal demonstration program under the Public Health Service Act focused on improving the treatment, prevention, and management of sickle cell disease (a genetic blood disorder that affects red blood cells) and its complications. It also encourages broader research into heritable blood disorders (inherited conditions affecting blood) to better understand their causes and develop cures.
Key Provisions
- Program Expansion: Updates the program's scope to explicitly include the treatment of sickle cell disease, as well as the prevention and treatment of its complications (such as pain crises, infections, or organ damage).
- Funding Mechanisms: Allows the Secretary of Health and Human Services (HHS) to provide support through grants (direct funding awards), contracts, or cooperative agreements (collaborative partnerships), rather than limiting it to contracts only.
- Authorization of Appropriations: Allocates $8,205,000 annually for fiscal years 2025 through 2029 to fund the program.
- Sense of Congress Statement: Expresses congressional support for ongoing research to deepen knowledge of heritable blood disorders and pursue cures.
Significant Changes to Existing Law
- Scope Broadening: Previously, the program emphasized "prevention and treatment of sickle cell disease" in multiple sections; now it adds focus on "prevention and treatment of complications," making the program more comprehensive.
- Funding Flexibility: Shifts from contract-only awards to include grants and cooperative agreements, offering more options for HHS to partner with organizations.
- Increased and Extended Funding: Raises the annual appropriation from $4,455,000 (for fiscal years 2019–2023) to $8,205,000 and extends it to fiscal years 2025–2029, effectively reauthorizing the program with enhanced resources.
Potential Impacts
- On Government Agencies: Increases funding responsibilities for HHS, particularly the Health Resources and Services Administration, to administer the expanded program, potentially leading to more grants and partnerships with state or local health entities.
- On Citizens: Improves access to specialized care, research, and preventive services for individuals with sickle cell disease (primarily affecting African Americans and other communities of color), which could reduce health disparities and improve quality of life.
- On International Relations: Minimal direct impact, though enhanced U.S. research could contribute to global knowledge-sharing on genetic blood disorders.
Main Stakeholders Affected
- Patients and Families: Individuals with sickle cell disease or other heritable blood disorders, who may benefit from better treatments and prevention efforts.
- Healthcare Providers and Organizations: Hospitals, clinics, and nonprofits involved in blood disorder care, eligible for new grants or agreements.
- Researchers and Institutions: Universities and medical centers focused on genetic research, encouraged by the sense-of-Congress provision to pursue studies on causes and cures.
- Federal Government: HHS and Congress, through increased appropriations and program oversight.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens existing public health authority under the Public Health Service Act without creating new mandates, ensuring compliance with federal spending rules for health programs.
- Constitutional: Aligns with Congress's power to regulate interstate commerce and promote general welfare (via health funding), with no apparent conflicts.
- Political: Bipartisan sponsorship (from both parties) highlights rare consensus on addressing health inequities; the funding increase may spark debates on federal spending priorities, but it promotes equity for underserved populations without controversial elements.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Rep. Veasey, Marc A. [D-TX-33], Rep. Carter, Troy A. [D-LA-2], Rep. Davis, Danny K. [D-IL-7], Rep. Kiggans, Jennifer A. [R-VA-2], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Bishop, Sanford D. [D-GA-2]
Recent Actions
- 2025-03-03: Referred to the House Committee on Energy and Commerce.
- 2025-03-03: Introduced in House
- 2025-03-03: Introduced in House
Bill Versions
- Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 — issued 2025-03-03 — PDF (3 pages)